Associations - PIK3CA mutation

BIOMARKER:

PIK3CA mutation

Entrez ID:

5290

Related biomarkers:

‹

›

PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + alpelisib + LJM-716 Sensitive: C3 – Early Trials Clin Cancer Res - 6 days trastuzumab + alpelisib + LJM-716 Sensitive : C3 Clin Cancer Res - 6d
PIK3CA mutation PIK3CA mutation	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	BKM120 Sensitive: B - Late Trials BKM120 Sensitive : B
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	alpelisib Sensitive: B - Late Trials alpelisib Sensitive : B
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	GDC-0068 Sensitive: B - Late Trials GDC-0068 Sensitive : B
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	panitumumab Resistant: B - Late Trials panitumumab Resistant : B
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	neratinib Resistant: B - Late Trials neratinib Resistant : B
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	lapatinib Resistant: B - Late Trials lapatinib Resistant : B
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Sensitive: B - Late Trials trastuzumab Sensitive : B
PIK3CA mutation PIK3CA mutation	Colorectal Cancer CRC	atezolizumab + cobimetinib Sensitive: B - Late Trials atezolizumab + cobimetinib Sensitive : B
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	everolimus Sensitive: B - Late Trials everolimus Sensitive : B
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	erlotinib Resistant: B - Late Trials erlotinib Resistant : B
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab + MEN1611 Sensitive: C2 – Inclusion Criteria trastuzumab + MEN1611 Sensitive : C2
PIK3CA mutation PIK3CA mutation	Uterine Cancer Uterine Cancer	copanlisib Sensitive: C2 – Inclusion Criteria copanlisib Sensitive : C2
PIK3CA mutation PIK3CA mutation	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	MEN1611 Sensitive: C2 – Inclusion Criteria MEN1611 Sensitive : C2
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	GDC-0032 Sensitive: C2 – Inclusion Criteria GDC-0032 Sensitive : C2
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	alpelisib Sensitive: C2 – Inclusion Criteria alpelisib Sensitive : C2
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	U3-1402 Sensitive: C3 – Early Trials U3-1402 Sensitive : C3
PIK3CA mutation PIK3CA mutation	Triple Negative Breast Cancer Triple Negative Breast Cancer	everolimus Sensitive: C3 – Early Trials everolimus Sensitive : C3
PIK3CA mutation PIK3CA mutation	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PIK3CA mutation PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck SCCHN	temsirolimus Sensitive: C3 – Early Trials temsirolimus Sensitive : C3
PIK3CA mutation PIK3CA mutation	Non Small Cell Lung Cancer NSCLC	X-396 Resistant: C3 – Early Trials X-396 Resistant : C3
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	bevacizumab Sensitive: C3 – Early Trials bevacizumab Sensitive : C3
PIK3CA mutation PIK3CA mutation	Breast Cancer Breast Cancer	ribociclib Sensitive: C3 – Early Trials ribociclib Sensitive : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES